Compare AGCO Corporation (AGCO) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs Amphastar Pharmaceuticals Inc — how do they compare? AGCO Corporation trades at $102.25 (market cap $7.06B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: AGCO Corporation is far larger — about 8.2× Amphastar Pharmaceuticals Inc's market cap, and AGCO Corporation pays a 1.19% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGCO | AMPH | |
|---|---|---|
Market Cap | $7.06B | $863.95M |
Sector | Industrials | Health |
52-Week High | $140.49 | $30.81 |
52-Week Low | $100.14 | $16.87 |
Enterprise Value | $9.33B | $1.26B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $102.83, up 1.18% on the day, but faces bearish technical signals with the stock trading near key support at $102. The agricultural equipment manufacturer reported mixed Q2 2026 results, missing earnings estimates but maintaining a solid balance sheet with $612 million in cash. Recent leadership changes and multiple securities investigations create uncertainty, though the company's valuation remains attractive with a P/E of 14.22 and P/S of 0.73.
While AGCO's fundamentals show resilience with positive cash flow and reasonable valuation, near-term headwinds from weaker industry conditions and legal scrutiny present significant risks. The 37.9% analyst buy rating and $124.63 price target suggest potential upside, but investors should weigh the bearish technical outlook against the company's long-term positioning in precision agriculture.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
